[EN] MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS)<br/>[FR] MODULATEURS DE PROTÉINES D'ÉCHANGE DIRECTEMENT ACTIVÉES PAR L'AMPC (EPAC)
申请人:UNIV TEXAS
公开号:WO2013119931A1
公开(公告)日:2013-08-15
Embodiments of the invention are directed to compounds that inhibit an activity of EP AC proteins and methods of using the same. The inventors have developed a sensitive and robust high throughput screening (HTS) assay for the purpose of identifying EPAC specific inhibitors (Tsalkova et al. (2012) PLOS ONE 7(1 ):e30441).
该发明的实施例涉及抑制EPAC蛋白活性的化合物以及使用这些化合物的方法。发明人已经开发了一种敏感且稳健的高通量筛选(HTS)测定方法,用于识别EPAC特异性抑制剂(Tsalkova等人(2012年)PLOS ONE 7(1):e30441)。
MODULATORS OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS)
申请人:The Board of Regents of the University of Texas System
公开号:US20150110809A1
公开(公告)日:2015-04-23
Embodiments of the invention are directed to compounds that inhibit an activity of EP AC proteins and methods of using the same. The inventors have developed a sensitive and robust high throughput screening (HTS) assay for the purpose of identifying EPAC specific inhibitors (Tsalkova et al. (2012) PLOS ONE 7 (1):e30441).
本发明的实施例涉及抑制EPAC蛋白活性的化合物及其使用方法。发明人开发了一种灵敏且强大的高通量筛选(HTS)检测方法,以识别EPAC特异性抑制剂(Tsalkova等人(2012)PLOS ONE 7(1):e30441)。
US9539256B2
申请人:——
公开号:US9539256B2
公开(公告)日:2017-01-10
Identification and Characterization of Small Molecules as Potent and Specific EPAC2 Antagonists
作者:Haijun Chen、Tamara Tsalkova、Oleg G. Chepurny、Fang C. Mei、George G. Holz、Xiaodong Cheng、Jia Zhou
DOI:10.1021/jm3014162
日期:2013.2.14
EPAC1 and EPAC2, two isoforms of exchange proteins directly activated by cAMP (EPAC), respond to the second messenger cAMP and regulate a wide variety of intracellular processes under physiological and pathophysiological circumstances. Herein, we report the chemical design, synthesis, and pharmacological characterization of three different scaffolds (diarylsulfones, N,N-diarylamines, and arylsulfonamides) as highly potent and selective antagonists of EPAC2. Several selective EPAC2 antagonists have been identified including 20i (HJC0350), which has an apparent IC50 of 0.3 mu M for competing with 8-NBD-cAMP binding of EPAC2 and is about 133-fold more potent than cAMP. Compounds 1 (ESI-05), 14c (HJC0338), and 20i, selected from each series, have exhibited no inhibition of EPAC1-mediated Rap1-GDP exchange activity at 25 mu M, indicating that they are EPAC2-specific antagonists. Moreover, live-cell imaging studies using EPAC1, EPAC2, or PICA FRET sensor also demonstrate that 20i functions as an EPAC2 specific antagonist.